COCH — Envoy Medical Income Statement
0.000.00%
Last trade - 00:00
- $46.26m
- $46.13m
- $0.32m
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0.31 | 0.237 | 0.316 |
Cost of Revenue | |||
Gross Profit | -0.459 | -0.72 | -0.473 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 7.18 | 8.94 | 18.7 |
Operating Profit | -6.87 | -8.71 | -18.4 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -8.68 | -15.9 | -29.9 |
Net Income After Taxes | -8.68 | -15.9 | -29.9 |
Net Income Before Extraordinary Items | |||
Net Income | -8.68 | -15.9 | -29.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -8.68 | -15.9 | -29.9 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -0.444 | -0.814 | -2.38 |